Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Medtech Magnolia fails to revive $2.1m verdict at Fed Circ

9 March 2026 Appeals court upholds lower court’s ruling, clarifying key legal questions concerning patent claims for blood‑testing devices.

Americas

Abbott IP chief: ‘Firms without AI policies scare me’

5 March 2026 The healthcare company’s chief IP counsel is researching how law firms and patent attorneys are using AI tools to inform its own guidelines for external legal providers.

Americas

Moderna inks billion-dollar deal to settle long-running Spikevax dispute

5 March 2026 Moderna settles, agreeing to part with up to $2.25 billion to avoid a trial and secure a licence to continue using the platform underpinning its COVID-19 vaccine.

More features

Emotional Perception: What next for patent holders?

Semaglutide patent battle heats up with new blow for Novo in India

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features